Moss 5 August, 2024
Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic tests, is pleased to announce the appointment of Frank Frantzen as Chief Technology Officer (CTO).
Frank Frantzen has more than 35 years of experience from the diagnostic industry. He has served as principal scientist and has directed larger R&D units in the international IVD companies Axis-Shield, Alere and Abbott. Mr. Frantzen left his Senior Director R&D position at Abbott in 2021 and has until recently served as Chief Technology Officer in CardiNor AS. Mr. Frantzen also served as a board member of Gentian Diagnostics from May 2022 to December 2023.
Mr. Frank Frantzen holds a master’s degree in chemistry and a Ph.D. (Dr.philos.) in chemistry/biotechnology/IVD-technology, both from the Norwegian University of Science and Technology in Trondheim.
Over the years, Frank has been involved in launching several international blockbuster IVD products, with homocysteine and the Afinion POC system (instrument and assays) as examples. In 2019, Frank was awarded the Abbott’s Scientific Governing Board Innovation Award for his work on the analysis of HbA1c, the principal marker for diagnosis of diabetes. He was the same year also introduced into Abbott's Volwiler Society, an honorary society for Abbotts most distinguished scientists and engineers.
About Gentian Diagnostics
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in vitro diagnostic reagents. Gentian’s expertise and focus lies within homogenous immunoassays, specifically infections, inflammations, kidney failures and congestive heart failures. By converting existing and clinically relevant biomarkers to the most efficient automated, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian is headquartered in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA, and China. For more information, please visit www.gentian.com.
IR contact:
Njaal Kind, CEO
njaal.kind@gentian.no
+47 919 06 525 (mobile)